Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene Returns To Forma’s Door, This Time With Option To Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

The big biotech signed an expansive collaboration with the drug discovery company spanning multiple targets and numerous therapeutic areas. Celgene agreed to pay $225 million upfront and could eventually buy the company.

You may also be interested in...



Third Rock Launches Nurix With Ambitions Of Next-Gen Velcade

The recently uncovered biotech a la Third Rock and The Column Group is focused on the ubiquitin protease pathway and its applications in oncology.

Deals Of The Week Examines How Amarin Reeled In A Partner For Vascepa

Amarin signed Kowa Pharmaceuticals America as a commercial partner for its fish oil pill, more than doubling the number of sales reps detailing the medicine. Forma signed a second drug discovery pact with Celgene, while Baxter bolstered its hemophilia franchise by buying out partner Chatham Therapeutics.

Forma To Rev Its Discovery Engine For Deubiquitination

In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS077063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel